middle.news
Ceretas Advances Alzheimer’s Ultrasound Device with $8 Million IPO and Phase 2 Trial Start
8:24am on Monday 31st of August, 2026 AEST
•
Healthcare
Read Story
Ceretas Advances Alzheimer’s Ultrasound Device with $8 Million IPO and Phase 2 Trial Start
8:24am on Monday 31st of August, 2026 AEST
Key Points
FY26 revenue surged 21,615% to $1.28 million, driven by government grants
Net loss widened to $1.63 million amid ramped-up R&D and corporate costs
Successful $8 million IPO completed post-year end to fund Phase 2 trial and device development
Phase 1 trial published showing safety and reduction in behavioural symptoms
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Ceretas (ASX:CTS)
OPEN ARTICLE